JP2021534253A - 液体ベンダムスチン医薬組成物 - Google Patents

液体ベンダムスチン医薬組成物 Download PDF

Info

Publication number
JP2021534253A
JP2021534253A JP2021532537A JP2021532537A JP2021534253A JP 2021534253 A JP2021534253 A JP 2021534253A JP 2021532537 A JP2021532537 A JP 2021532537A JP 2021532537 A JP2021532537 A JP 2021532537A JP 2021534253 A JP2021534253 A JP 2021534253A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
bendamustine
amount
water
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021532537A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020035806A5 (https=
JP2021534253A5 (https=
Inventor
マルコム ニール アンドリュー
ノリス ノエル
Original Assignee
ホスピーラ オーストラリア ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホスピーラ オーストラリア ピーティーワイ リミテッド filed Critical ホスピーラ オーストラリア ピーティーワイ リミテッド
Publication of JP2021534253A publication Critical patent/JP2021534253A/ja
Publication of JPWO2020035806A5 publication Critical patent/JPWO2020035806A5/ja
Publication of JP2021534253A5 publication Critical patent/JP2021534253A5/ja
Priority to JP2024086001A priority Critical patent/JP2024109878A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021532537A 2018-08-17 2019-08-14 液体ベンダムスチン医薬組成物 Withdrawn JP2021534253A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024086001A JP2024109878A (ja) 2018-08-17 2024-05-28 液体ベンダムスチン医薬組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862764975P 2018-08-17 2018-08-17
US62/764,975 2018-08-17
US201862723725P 2018-08-28 2018-08-28
US62/723,725 2018-08-28
US201962815376P 2019-03-08 2019-03-08
US62/815,376 2019-03-08
PCT/IB2019/056903 WO2020035806A1 (en) 2018-08-17 2019-08-14 Liquid bendamustine pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024086001A Division JP2024109878A (ja) 2018-08-17 2024-05-28 液体ベンダムスチン医薬組成物

Publications (3)

Publication Number Publication Date
JP2021534253A true JP2021534253A (ja) 2021-12-09
JPWO2020035806A5 JPWO2020035806A5 (https=) 2022-08-10
JP2021534253A5 JP2021534253A5 (https=) 2022-08-10

Family

ID=69525233

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532537A Withdrawn JP2021534253A (ja) 2018-08-17 2019-08-14 液体ベンダムスチン医薬組成物
JP2024086001A Withdrawn JP2024109878A (ja) 2018-08-17 2024-05-28 液体ベンダムスチン医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024086001A Withdrawn JP2024109878A (ja) 2018-08-17 2024-05-28 液体ベンダムスチン医薬組成物

Country Status (7)

Country Link
US (1) US12246007B2 (https=)
EP (1) EP3836921B1 (https=)
JP (2) JP2021534253A (https=)
AU (1) AU2019321089A1 (https=)
CA (1) CA3108321A1 (https=)
ES (1) ES3055021T3 (https=)
WO (1) WO2020035806A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022508807A (ja) 2018-10-16 2022-01-19 ユーエス・ナノ・フード・アンド・ドラッグ・インコーポレーテッド 腫瘍内注射製剤
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
US11752165B2 (en) * 2020-04-13 2023-09-12 US Nano Food & Drug, Inc Basic chemotherapeutic intratumour injection formulation
CN121465991A (zh) * 2020-04-15 2026-02-06 卡希夫生物科学有限公司 卡非佐米的稳定的即稀释型制剂
GB202118175D0 (en) 2021-12-15 2022-01-26 Arecor Ltd Novel composition
US11707450B1 (en) * 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine
CN118415976A (zh) * 2024-05-09 2024-08-02 深圳开悦生命科技有限公司 多环化合物注射剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016005995A2 (en) * 2014-07-10 2016-01-14 Leiutis Pharmaceuticals Pvt. Ltd. Glycol free stable liquid compositions of bendamustine
CN105726472A (zh) * 2016-03-25 2016-07-06 南京康玻斯医药科技有限公司 苯达莫司汀药剂组合物及应用
WO2017175098A1 (en) * 2016-04-05 2017-10-12 Leiutis Pharmaceuticals Pvt Ltd Stable liquid pharmaceutical formulations of bendamustine
US20180055823A1 (en) * 2016-08-31 2018-03-01 Mahendra R. Patel Bendamustine Solution Formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2326306A1 (en) 2008-09-25 2011-06-01 Cephalon, Inc. Liquid formulations of bendamustine
PL3158991T3 (pl) 2010-01-28 2021-09-27 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
US20130210878A1 (en) 2012-01-24 2013-08-15 Innopharma, Inc. Bendamustine compositions and methods therefore
CA2867295C (en) 2012-03-20 2020-08-11 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
PL2827863T3 (pl) 2012-03-20 2019-07-31 Eagle Pharmaceuticals, Inc. Ciekła kompozycja do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania
US20160235717A1 (en) * 2013-10-11 2016-08-18 Luitpold Pharmaceuticals, Inc. Bendamustine pharmaceutical compositions
WO2016059590A1 (en) 2014-10-16 2016-04-21 Piramal Enterprises Limited Stable injectable composition of small molecule drugs and process for its preparation
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016005995A2 (en) * 2014-07-10 2016-01-14 Leiutis Pharmaceuticals Pvt. Ltd. Glycol free stable liquid compositions of bendamustine
CN105726472A (zh) * 2016-03-25 2016-07-06 南京康玻斯医药科技有限公司 苯达莫司汀药剂组合物及应用
WO2017175098A1 (en) * 2016-04-05 2017-10-12 Leiutis Pharmaceuticals Pvt Ltd Stable liquid pharmaceutical formulations of bendamustine
US20180055823A1 (en) * 2016-08-31 2018-03-01 Mahendra R. Patel Bendamustine Solution Formulations

Also Published As

Publication number Publication date
EP3836921A1 (en) 2021-06-23
EP3836921C0 (en) 2025-10-08
EP3836921B1 (en) 2025-10-08
US12246007B2 (en) 2025-03-11
EP3836921A4 (en) 2022-04-20
JP2024109878A (ja) 2024-08-14
US20210275500A1 (en) 2021-09-09
WO2020035806A1 (en) 2020-02-20
AU2019321089A1 (en) 2021-02-11
CA3108321A1 (en) 2020-02-20
ES3055021T3 (en) 2026-02-09

Similar Documents

Publication Publication Date Title
JP2021534253A (ja) 液体ベンダムスチン医薬組成物
US7985757B2 (en) Argatroban formulation
CA2948148C (en) Formulations of cyclophosphamide liquid concentrate
RU2519764C1 (ru) Стабильная готовая к применению композиция парацетамола для инъекций
JP6159567B2 (ja) 既製のゲムシタビン注入溶液
KR20020093839A (ko) 에스몰올 제제
CA2410446C (en) Esmolol formulation
BR112012031928B1 (pt) Composições farmacêuticas as quais incluem paracetamol e processo para preparação do mesmo
CA3045794C (en) LIQUID LEVOTHYROXINE FORMULAS
US11642358B1 (en) Stable pharmaceutical formulation
US20160144033A1 (en) Concentrated acetaminophen solution
HK1178053B (en) Argatroban formulation comprising an acid as solubilizer
HK1123193B (en) Argatroban formulation comprising an acid as solubilizer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230614

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240207

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240528